Form 10-K Intellia Therapeutics, For: Dec 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. HUBS
3. NUE
4. SPY
5. AAPL
6. TRMD
7. RARE
8. INTU
9. AUTO
10. AZN

Go back to Form 10-K Intellia Therapeutics, For: Dec 31

Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'

February 23, 2024 9:27 AM EST

Evercore ISI analyst Liisa Bayko reiterated an Outperform rating and $70.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "2024 will be a year of execution for NTLA with P3 for NTLA-2001 in ATTR-CM ongoing while preparing P3 for ATTR-PN and HAE. P3 MAGNITUDE study for NTLA-2001 in ATTR-CM kicked off end of last year and will dose the first patient in 1Q. The trial size is slightly greater than that of HELIOS-B (ALNY). We estimate enrollment to complete around year-end 2024 and topline readout in 2H27.... More

Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'

February 23, 2024 9:25 AM EST

Citi analyst David Lebowitz reiterated a Neutral rating and $31.00 price target on Intellia Therapeutics (NASDAQ: NTLA).

The analyst comments "Following competitor Alnylams HELIOS-B updates (HERE), mgt. remains confident in the event-driven design of NTLA-2001s Ph3 MAGNITUDE trial. While there are no planned... More

Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'

February 23, 2024 9:19 AM EST

Goldman Sachs analyst Salveen Richter downgraded Intellia Therapeutics (NASDAQ: NTLA) from Buy to Neutral with a price target of $32.00.

The analyst comments "NTLA reported 4Q EPS and reiterated the near-term catalyst path for NTLAs in vivo CRISPR gene-edited therapies, which include: 1) longer-term Ph1 data from NTLA-2001 in ATTR-cardiomyopathy (ATTR-CM) and... More